THURSDAY, Sept. 24, 2020 (HealthDay News) — The final stage of clinical trials<\/a> for Johnson & Johnson’s coronavirus vaccine<\/a> have started, the company announced Tuesday.<\/p>\n The Phase 3 trials will include 60,000 people and be the largest for a coronavirus vaccine<\/a> in the United States, The New York Times<\/i> reported.<\/p>\n Johnson & Johnson’s final-stage trials began months after similar trials of other coronavirus vaccines<\/a> in the United States, but it may have some advantages over the other vaccines<\/a> because it doesn’t need to be stored in subzero temperatures and may require just one dose instead of two, according to experts.<\/p>\n “It would be fabulous if we had something at a single dose,” because it could speed efforts to curb the pandemic, Dr. Judith Feinberg, vice chairwoman for research in medicine at West Virginia University, told the Times<\/i>. She’s not involved in the vaccine research.<\/p>\n Johnson & Johnson might know by the end of the year if the vaccine is safe and effective, Dr. Paul Stoffels, the company’s chief scientific officer, said at a news conference on Tuesday, The Times<\/i> reported.<\/p>\n ![\"MedicalNews\"](\"https:\/\/images.medicinenet.com\/images\/HealthDay\/healthday.png\")
Copyright \u00a9 2019 HealthDay. All rights reserved.<\/p>\n
\n
\n ![](\"https:\/\/images.medicinenet.com\/\/images\/slideshow\/pertussis-whooping-cough-s1-girl-cough-in-bed.jpg\"\/)
\n